{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:26:07Z","timestamp":1793816767661,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vaccine.2021.02.023","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T22:55:00Z","timestamp":1614207300000},"page":"2514-2523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Biosecurity risks associated with vaccine platform technologies"],"prefix":"10.1016","volume":"40","author":[{"given":"Jonas B.","family":"Sandbrink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Koblentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.023_b0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/hs.2017.0044","article-title":"Human agency and global catastrophic biorisks","volume":"15","author":"Millett","year":"2017","journal-title":"Health Secur"},{"key":"10.1016\/j.vaccine.2021.02.023_b0010","unstructured":"Adalja A.A., Watson M., Cicero A., Inglesby T.V. Vaccine Platforms: State of the Field and Looming Challenges. Johns Hopkins Center for Health Security; 2019."},{"key":"10.1016\/j.vaccine.2021.02.023_b0015","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1056\/NEJMcibr2009737","article-title":"Amplifying RNA vaccine development","volume":"382","author":"Fuller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.023_b0020","article-title":"Covid Vaccine Front-Runner Is Months Ahead of Her Competition","year":"2020","journal-title":"Bloomberg"},{"issue":"6499","key":"10.1016\/j.vaccine.2021.02.023_b0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.02.023_b0030","doi-asserted-by":"crossref","first-page":"608460","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA vaccines: a suitable platform for tackling emerging pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0035","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/vaccines6020029","article-title":"Clinical advances in viral-vectored influenza vaccines","volume":"6(2)","author":"Sebastian","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.023_b0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41590-017-0007-9","article-title":"Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic","volume":"19","author":"Graham","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2021.02.023_b0055","doi-asserted-by":"crossref","unstructured":"Sadoff J., Le Gars M., Shukarev G., Heerwegh D., Truyers C., de Groot A.M., et al. Interim Results of a Phase 1\u20132a Trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2034201.","DOI":"10.1056\/NEJMoa2034201"},{"key":"10.1016\/j.vaccine.2021.02.023_b0060","doi-asserted-by":"crossref","first-page":"5567","DOI":"10.1128\/JVI.00405-09","article-title":"Effect of preexisting immunity on an adenovirus vaccine vector. In vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo","volume":"83","author":"Pichla-Gollon","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018526","article-title":"Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5\/HIV-1 vaccine candidate in humans","volume":"6","author":"Pine","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.023_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/mic.0.049601-0","article-title":"Pre-existing immunity against vaccine vectors \u2013 friend or foe?","volume":"159","author":"Saxena","year":"2013","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2021.02.023_b0075","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.02.023_b0080","unstructured":"Herper M, Branswell H. Moderna\u2019s Covid-19 vaccine is strongly effective, early look at data show. STAT 2020. https:\/\/www.statnews.com\/2020\/11\/16\/modernas-covid-19-vaccine-is-strongly-effective-early-look-at-data-show\/ (accessed November 16, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0085","unstructured":"Pfizer and BioNTech Covid-19 vaccine is 95% effective, full results show. STAT 2020. https:\/\/www.statnews.com\/2020\/11\/18\/pfizer-biontech-covid19-vaccine-fda-data\/ (accessed November 23, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0090","doi-asserted-by":"crossref","unstructured":"Kis Z, Shattock R, Shah N, Kontoravdi C. Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. vol. 14. Wiley-VCH Verlag; 2019. https:\/\/doi.org\/10.1002\/biot.201800376.","DOI":"10.1002\/biot.201800376"},{"key":"10.1016\/j.vaccine.2021.02.023_b0095","unstructured":"Will supply chain demands freeze Pfizer and BioNTech out of a big chunk of the Covid-19 market? Endpoints News n.d. https:\/\/endpts.com\/will-supply-chain-demands-freeze-pfizer-and-biontech-out-of-a-big-chunk-of-the-covid-19-market\/ (accessed August 31, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0100","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2021.02.023_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6030037","article-title":"Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system","volume":"6","author":"Mohsen","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.023_b0110","first-page":"45","article-title":"Inactivated viral vaccines","author":"Sanders","year":"2014","journal-title":"Vacc Anal Strateg Princ Control"},{"key":"10.1016\/j.vaccine.2021.02.023_b0115","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1586\/14760584.2015.1067144","article-title":"Bioreactor concepts for cell culture-based viral vaccine production","volume":"14","author":"Gallo-Ram\u00edrez","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.02.023_b0120","first-page":"635","article-title":"The double-edged sword: How evolution can make or break a live-attenuated virus vaccine","volume":"4","author":"Hanley","year":"2011","journal-title":"Evolution"},{"key":"10.1016\/j.vaccine.2021.02.023_b0125","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3389\/fimmu.2019.01250","article-title":"Attenuation of human respiratory viruses by synonymous genome recoding","volume":"10","author":"Le Nou\u00ebn","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0130","unstructured":"National Academies of Sciences, Engineering, and Medicine. Biodefense in the Age of Synthetic Biology. Washington, DC: The National Academies Press; 2018."},{"key":"10.1016\/j.vaccine.2021.02.023_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00103-019-03061-2","article-title":"Developing vaccines against epidemic-prone emerging infectious diseases","volume":"63","author":"Bernasconi","year":"2020","journal-title":"Bundesgesundheitsblatt"},{"key":"10.1016\/j.vaccine.2021.02.023_b0140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3934\/publichealth.2019.4.502","article-title":"Recurrent ebolavirus disease in the democratic Republic of Congo: update and challenges","volume":"6","author":"Inungu","year":"2019","journal-title":"AIMS Public Health"},{"key":"10.1016\/j.vaccine.2021.02.023_b0145","unstructured":"Staines R. J&J\u2019s Ebola vaccine approved in EU 2020. https:\/\/pharmaphorum.com\/news\/jjs-ebola-vaccine-approved-in-eu\/ (accessed November 20, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0150","unstructured":"World Health Organisation. Draft landscape of COVID-19 candidate vaccines n.d. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (accessed January 9, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0155","doi-asserted-by":"crossref","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2020;0:null. https:\/\/doi.org\/10.1056\/NEJMoa2035389.","DOI":"10.1056\/NEJMoa2035389"},{"key":"10.1016\/j.vaccine.2021.02.023_b0160","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.023_b0165","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"0","author":"Folegatti","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2021.02.023_b0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1089\/bsp.2006.4.276","article-title":"The dual-use dilemma for the life sciences: perspectives, conundrums, and global solutions","volume":"4","author":"Atlas","year":"2006","journal-title":"Biosecurity Bioterrorism Biodefense Strategy Pract Sci"},{"key":"10.1016\/j.vaccine.2021.02.023_b0175","unstructured":"Central Intelligence Agency. Comprehensive Report of the Special Advisor to the DCI on Iraq\u2019s WMD, with Addendums (Duefler Report). vol. 3. Washington DC: U.S. Government Office; 2005."},{"key":"10.1016\/j.vaccine.2021.02.023_b0180","series-title":"The Soviet Biological Weapons Program: A History","author":"Leitenberg","year":"2012"},{"key":"10.1016\/j.vaccine.2021.02.023_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007129","article-title":"Horsepox and the need for a new norm, more transparency, and stronger oversight for experiments that pose pandemic risks","volume":"14","author":"Inglesby","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2021.02.023_b0190","doi-asserted-by":"crossref","unstructured":"Ben Ouagrham-Gormley S. Barriers to Bioweapons: The Challenges of Expertise and Organization for Weapons Development. Ithaca: Cornell University Press; 2014.","DOI":"10.7591\/cornell\/9780801452888.001.0001"},{"key":"10.1016\/j.vaccine.2021.02.023_b0195","series-title":"Phantom Menace or Looming Danger? A New Framework for Assessing Bioweapons Threats","author":"Vogel","year":"2012"},{"key":"10.1016\/j.vaccine.2021.02.023_b0200","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1586\/erv.09.29","article-title":"Strategies to overcome host immunity to adenovirus vectors in vaccine development","volume":"8","author":"Thacker","year":"2009","journal-title":"Expert Rev Vac"},{"key":"10.1016\/j.vaccine.2021.02.023_b0205","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"Yu","year":"2012","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0210","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/mt.2011.92","article-title":"Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis","volume":"19","author":"Miest","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2021.02.023_b0215","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vac Immunother"},{"key":"10.1016\/j.vaccine.2021.02.023_b0220","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1089\/hum.2008.091","article-title":"Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses","volume":"19","author":"Weaver","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2021.02.023_b0225","first-page":"493","article-title":"Evading the immune response upon in vivo gene therapy with viral vectors","volume":"11","author":"Sack","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2021.02.023_b0230","doi-asserted-by":"crossref","first-page":"e805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv Virol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0235","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gt.2014.124","article-title":"Preferable sites and orientations of transgene inserted in the adenovirus vector genome: the E3 site may be unfavorable for transgene position","volume":"22","author":"Suzuki","year":"2015","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2021.02.023_b0240","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/21645515.2018.1513439","article-title":"Poxviral promoters for improving the immunogenicity of MVA delivered vaccines","volume":"15","author":"Alharbi","year":"2018","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2021.02.023_b0245","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2021.02.023_b0250","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1086\/428843","article-title":"New considerations in infectious disease outbreaks: the threat of genetically modified microbes","volume":"40","author":"Gilsdorf","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.023_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10736709908436760","article-title":"Biological weapons in the former Soviet Union: an interview with Dr","volume":"6","author":"Tucker","year":"1999","journal-title":"Kenneth Alibek. Nonproliferation Rev"},{"key":"10.1016\/j.vaccine.2021.02.023_b0260","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1089\/hs.2017.0061","article-title":"The de novo synthesis of horsepox virus: implications for biosecurity and recommendations for preventing the reemergence of smallpox","volume":"15","author":"Koblentz","year":"2017","journal-title":"Health Secur"},{"key":"10.1016\/j.vaccine.2021.02.023_b0265","unstructured":"World Health Organisation. The Independent Advisory Group on Public Health Implications of Synthetic Biology Technology Related to Smallpox. A Report to the Director-General of the WHO. Geneva: 2015."},{"key":"10.1016\/j.vaccine.2021.02.023_b0270","unstructured":"The United States Government. United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern. 2012."},{"key":"10.1016\/j.vaccine.2021.02.023_b0275","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00040-18","article-title":"A critical analysis of the scientific and commercial rationales for the de novo synthesis of horsepox virus","volume":"3","author":"Koblentz","year":"2018","journal-title":"MSphere"},{"key":"10.1016\/j.vaccine.2021.02.023_b0280","article-title":"Data check: U.S. government share of basic research funding falls below 50%","author":"Mervis","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.02.023_b0285","unstructured":"Herper M. Covid-19 vaccine from Pfizer and BioNTech is strongly effective, data show. STAT 2020. https:\/\/www.statnews.com\/2020\/11\/09\/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate\/ (accessed November 14, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0290","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.02.023_b0295","unstructured":"World Health Organisation. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response. 2019."},{"key":"10.1016\/j.vaccine.2021.02.023_b0300","unstructured":"Gavi, the Vaccine Alliance. First-of-its-kind vaccine agreement helps end Ebola outbreak in eastern DRC 2020. https:\/\/www.gavi.org\/news\/media-room\/first-its-kind-vaccine-agreement-helps-end-ebola-outbreak-eastern-drc (accessed November 20, 2020)."},{"key":"10.1016\/j.vaccine.2021.02.023_b0305","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccines Immunother"},{"issue":"20","key":"10.1016\/j.vaccine.2021.02.023_b0310","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.023_b0315","article-title":"3rd major COVID-19 vaccine shown to be effective and cheaper","author":"Kirka","year":"2020","journal-title":"AP NEWS"},{"key":"10.1016\/j.vaccine.2021.02.023_b0320","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0325","doi-asserted-by":"crossref","first-page":"e0006108","DOI":"10.1371\/journal.pntd.0006108","article-title":"A thermostable messenger RNA based vaccine against rabies","volume":"11","author":"Stitz","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"1271\u20131283","key":"10.1016\/j.vaccine.2021.02.023_b0330","first-page":"e16","article-title":"A Thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.02.023_b0335","article-title":"Preventing global catastrophic biological risks \u2013 lessons and recommendations from a Tabletop exercise held at the 2020 Munich security conference","author":"Cameron","year":"2020","journal-title":"Nuclear Threat Initiative"},{"key":"10.1016\/j.vaccine.2021.02.023_b0340","unstructured":"Biotechnology and Biological Sciences Research Council, Medical Research Council and The Wellcome Trust. Managing Risks of Misuse Associated with Grant Funding Activities: A joint Biotechnology and Biological Sciences Research Council, Medical Research Council and Wellcome Trust Policy Statement. 2005."},{"key":"10.1016\/j.vaccine.2021.02.023_b0345","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2019.00086","article-title":"Next steps for access to safe, secure DNA synthesis","volume":"7","author":"Diggans","year":"2019","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2018.00021","article-title":"A new approach to evaluating the risk-benefit equation for dual-use and gain-of-function research of concern","volume":"6","author":"Imperiale","year":"2018","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.vaccine.2021.02.023_b0355","unstructured":"U.S. Department of Health and Human Services. Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens. 2017."},{"key":"10.1016\/j.vaccine.2021.02.023_bib356","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00290-y","article-title":"Promoting versatile vaccine development for emerging pandemics","volume":"6","author":"Monrad","year":"2021","journal-title":"npj Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:24Z","timestamp":1759403424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":72,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0264410X21001717"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosecurity risks associated with vaccine platform technologies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}